Reading TELO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TELO free→Reading TELO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TELO free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is high, and the sector backdrop is a headwind, indicating challenges in the current market environment. If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting TELO and other Healthcare names. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $1.29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Over the trailing year it converted 0.50x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
18 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$235.
How much price usually moves either way.
On a bad day, this stock has moved -$793.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,284.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If the health care sector shows renewed growth, it could benefit Telomir's performance.
Confirms:Health care sector revenue growth accelerates back toward 10% or higher.
Disproves:Sector revenue growth is slowing down below current levels.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for TELO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Chief Financial Officer — Alan Weichselbaum: The departure of the CFO without any stated disagreement and subsequent appointment of a fractional CFO.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
TELO Telomir Pharmaceuticals Inc | — | — | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Finalize the acquisition of TELI Pharmaceuticals to expand market presence.
Newly stated in 2026-Q1. The acquisition of TELI Pharmaceuticals was completed on April 22, 2026, as per the material events. This strategic move aims to enhance Telomir's market presence. The financial impact of this acquisition is yet to be reflected in the financials.
“Telomir completed its acquisition of TELI Pharmaceuticals on April 22, 2026.”
Resolve the notice of delisting or failure to satisfy a continued listing rule.
Newly stated in 2025-Q4. Telomir has received a notice of delisting and submitted its preliminary proxy statement for the annual meeting. The resolution of this issue is critical for maintaining its listing status. Financials do not yet reflect any resolution progress.
“Telomir submitted its preliminary proxy statement in connection with its annual meeting of shareholders.”
Develop strategic partnerships to support research and development initiatives.
Newly stated in 2026-Q1. Telomir has announced new cellular data supporting an epigenetic modulation mechanism, indicating progress in strategic partnerships. The financials do not yet show the impact of these partnerships on revenue or profitability.
“Telomir announced new cellular data supporting an epigenetic modulation mechanism.”
Why it matters: A new CFO can change how the company reports finances. This could affect investor trust.
Confirms one read:The next quarterly report shows better financial numbers than the last quarter.
Confirms the other:The next quarterly report shows more losses or worse financial numbers.
Completion of Acquisition or Disposition of Assets The information contained in
Entry into a Material Definitive Agreement On April 22, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) completed its acquisition of TELI Pharmaceuticals, Inc. (“TELI”) pursuant to the previously announced merger agreement (the “Transaction”). The Transaction was previously approved by the Company’s shareholders during the Company’s annual shareholders meeting on March 23, 2026. At closing, the Company acquired 100% of TELI in exchange for a total of 34,389,710 restricted shares of the Co…
Unregistered Sales of Equity Securities. The information contained in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 23, 2026, at the Annual Meeting of the Shareholders of Telomir Pharmaceuticals, Inc. (the “Company”), the Company’s shareholders approved an amendment to the Company’s 2023 Omnibus Incentive Plan (the “Plan”) to (1) increase the number of shares reserved under the Plan from 6,500,000 to 11,500,000, and (2) to allow for the repricing of opt…